Corcept (CORT) Q4 Earnings: What To Expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) is set to announce its earnings results this Tuesday afternoon. Here’s what market participants can expect.
Last quarter, Corcept missed analysts’ revenue expectations, reporting revenues of $207.6 million, which marks a 13.7% increase year on year. The previous quarter was softer for the company, with full-year revenue guidance falling short of analysts’ forecasts and a notable miss on revenue estimates.
This quarter, the market anticipates Corcept’s revenue to grow by 36.3% year on year, an improvement from the 34.3% growth recorded in the same quarter last year. Analysts covering the company have largely reaffirmed their estimates over the past month, indicating their confidence in Corcept maintaining its trajectory heading into earnings. However, it is worth noting that Corcept has missed Wall Street’s revenue estimates multiple times in the last two years.
Comparing Corcept to its competitors in the branded pharmaceuticals sector, several have already disclosed their Q4 results, offering insights into potential outcomes for Corcept. Eli Lilly achieved year-on-year revenue growth of 42.6%, surpassing analysts’ expectations by 7.4%, while Bristol-Myers Squibb reported a modest revenue increase of 1.4%, exceeding estimates by 4.8%. Following their earnings reports, Eli Lilly's shares increased by 1.7%, and Bristol-Myers Squibb rose by 7.6%.
Concerns regarding potential tariffs and corporate tax reforms have led to significant market volatility in 2025. Although some branded pharmaceuticals stocks have performed well amid this turbulence, the sector has generally underperformed, with an average share price decline of 3.4% over the past month. Corcept has fared worse, experiencing a 23.3% drop in the same timeframe, as it approaches earnings with an average analyst price target of $76.40, compared to its current share price of $34.94.
As today’s younger investors may not have read the classic Gorilla Game: Picking Winners In High Technology, written over 20 years ago during the rise of Microsoft and Apple, they can still apply its principles. Stocks in enterprise software that capitalize on their own generative AI capabilities may represent the future “Gorillas” of the market. In line with this, we are pleased to share our Special Free Report on a profitable, fast-growing enterprise software stock that is already leveraging the automation wave and is poised to ride the generative AI trend next.
For more information and analysis, visit Inside Ticker.